Skip to main content

Relias Media has upgraded our site!

Please bear with us as we work through some issues in order to provide you with a better experience.

Thank you for your patience.

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

IMA new masthead1

April 15, 2011

View Archives Issues

  • Coffee: It's a GOOD thing!

    Women who drink little or no coffee appear to be at an increased risk of stroke compared with those who drink moderate amounts of coffee.
  • Effect of APCs and VPCs on the Risk of SCD

    This study concluded that subjects without a known history of any cardiovascular disease who demonstrated ventricular premature complexes on a 2-minute rhythm strip are significantly more likely to die from sudden cardiac death and the effect appears to be additive when atrial premature complexes occur concurrently.
  • When It Comes to Exercise, Maybe More is Better

    In this meta-analysis, individuals who exercised or had sex episodically had an increased risk of acute cardiac events during those activities compared with those who had high levels of habitual physical activity.
  • Belimumab Injection (Benlysta™)

    The FDA has approved the first new treatment for systemic lupus erythematosus (SLE) since 1955 when hydroxychloroquine and corticosteroids were approved. Belimumab is a recombinant human IgG1l monoclonal antibody specific for soluble human B lymphocyte stimulator protein (BLyS).
  • Clinical Briefs by Louis Kuritzky, MD

    The action to control cardiovascu-lar risk in diabetes (ACCORD) study is really three studies in one, providing information about blood pressure, glucose, and triglyceride treatment in high-risk diabetic patients.
  • ECG Review: A Woman with Heart Problems

    The ECG above was obtained in the office from a 47-year-old woman who said she had "heart problems" that resulted in hospitalization the month before.
  • Pharmacology Watch

    Apixaban and rivaroxaban near approval for nonvalvular atrial fibrillation; fidaxomicin for C. difficile infections; guideline for intensive insulin therapy; and FDA Actions.